TempraMed Granted U.S. Patent for Pen Agnostic, VIVI Cap Smart(TM) Further Strengthens Global Intellectual Property Position
TempraMed now holds 39 granted patents and registered designs across multiple jurisdictions, alongside pending applications.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TempraMed Technologies (TMPTF) received a U.S. patent for its VIVI Cap Smart platform on September 29, 2026, expanding its intellectual property protection.
Patent 12,746,342, filed on August 2, 2023, covers aspects of thermal insulation, smart monitoring and a cap adaptable to different injection pens. VIVI Cap Smart launched earlier in 2026. TempraMed's portfolio is also now available through McKesson Medical-Surgical's U.S. business-to-business network under an expanded agreement signed in June 2026. The network includes Optum Now, physician offices, long-term care and home health. U.S. online consumer distribution includes Amazon and Walmart.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointExpanded McKesson Medical-Surgical agreement signed in June 2026 makes the portfolio available through its U.S. business-to-business network.
- Minor pointU.S. patent 12,746,342 granted September 29, 2026, protects aspects of VIVI Cap Smart.
- Minor point39 granted patents and registered designs comprise TempraMed's intellectual property portfolio across multiple jurisdictions.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Patent Grant in the U.S. marks a major milestone in global IP strategy, advancing protection of its VIVI Cap Smart(TM) platform
Highlights
- U.S. patent officially granted by the U.S. Patent Office on September 29, 2026
- Covers core innovations underpinning TempraMed's VIVI Cap Smart™, which was launched earlier this year
- Strengthens the Company's global intellectual property position with 39 granted patents and registered designs across multiple jurisdictions, in addition to pending patent and design applications
- TempraMed portfolio now available across McKesson Medical-Surgical's U.S. B2B network, including Optum Now, physician offices, long-term care and home health, under an expanded agreement signed in June 2026
- Online B2C distribution in the U.S. through Amazon, and Walmart
Toronto, Ontario--(Newsfile Corp. - November 10, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that its U.S. patent application No. 18/264,059 (the "Patent") has now been formally granted by the U.S. Patent Office as patent 12,746,342.
The Patent, filed on August 2, 2023, was granted on September 29, 2026. The Patent includes claims covering key aspects of the Company's first of its kind, cap adaptable for use with different types of injection pens, VIVI Cap Smart™ which was launched earlier this year.
Without limiting the scope of the patent, it includes core elements of TempraMed's proprietary thermal-insulation and smart-monitoring architecture, while being pen agnostic
Being pen agnostic position VIVI Cap Smart™ as a differentiated platform at the intersection of home health, smart refrigeration, and the connected medical-device ecosystem. The innovation supports TempraMed's strategy to provide protection and connectivity to all injection devices for home care wearables & AI platforms.
"The formal grant of our U.S. patent represents a significant milestone in TempraMed's global intellectual property strategy," said Ron Nagar, CEO of TempraMed. "The U.S. is one of the most influential markets globally for advanced healthcare solutions, home care and health and wellness applications. Securing patent protection in this jurisdiction meaningfully strengthens our position and supports the expansion of our comprehensive product portfolio across America."
"Millions of Americans rely on multi dose injection pens every day, and many switch devices when their prescriptions change. Because VIVI Cap Smart™ is pen agnostic, it moves with them, delivering our unique temperature shield and data connectivity to almost every multi dose pen they use while our VIVI Med platform provides our unique temperature shield to many single dose autoinjectors and we plan to add data connectivity to it as well. As we build out new product categories and scale our platform, protecting our core innovations remains fundamental to unlocking long-term shareholder value and establishing global leadership in temperature-controlled medication management," commented Nagar.
About TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered, thermal insulation devices that work 24/7 without batteries or external power. With a product line already in market including VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. With operations in North America, Europe, and Asia, TempraMed will continue to expand globally offering a solution for medication protection and adherence.
Investors interested in learning more about TempraMed are encouraged to contact the Company at:
ir@tempramed.com
www.tempramed.com
Contact:
Julia Becker
Director & Capital Markets
T: +1 (604) 785-0850
E: julia@tempramed.com
Media
Brenda Zeitlin
Vice President, Marketing
E: brenda@tempramed.com
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE'S REGULATION SERVICES PROVIDER.
Cautionary Statements
This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation (collectively, "forward-looking statements"). Forward-looking statements may be identified by words such as "anticipate," "believe," "expect," "intend," "may," "plan," "will," "should," "strategy," "future," "potential," and similar expressions, or statements about events or conditions that may occur in the future.
Forward-looking statements in this press release include, without limitation, statements regarding: the expected scope and strength of the Company's intellectual property position in the U.S. and globally; the Company's commercialization strategy and plans for strategic engagement with appliance manufacturers and other potential partners; the anticipated market opportunity for VIVI Cap Smart™ in the U.S. and across America; the Company's plans to expand into multi-dose and multi-format medication storage systems; and the Company's ability to develop new product categories and expand its global IP portfolio.
Forward-looking statements are based on the opinions, expectations, and assumptions of management as of the date of this press release, including but not limited to: that the granted patent will provide meaningful commercial protection; that the Company will have sufficient financial resources to pursue its commercialization and IP strategies; that suitable commercialization partners will be identified and engaged on acceptable terms; and that market conditions in the the U.S. and America will support demand for the Company's products and technology platform.
Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied, including but not limited to challenges in enforcing intellectual property rights in foreign jurisdictions, including the U.S. ; the Company's ability to secure additional financing; changes in regulatory requirements or government policy; the ability to identify and secure commercialization partners; competitive developments in temperature-controlled medication storage and smart refrigeration technologies; general economic, market, and business conditions; and other risks described in the Company's public filings available on SEDAR+ at www.sedarplus.ca.
The forward-looking statements contained in this press release are made as of the date hereof. Except as required by applicable securities laws, the Company does not undertake any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323269
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When was TempraMed's VIVI Cap Smart U.S. patent granted?
TempraMed's U.S. patent 12,746,342 was granted on September 29, 2026. The application was filed on August 2, 2023.
What does TempraMed's VIVI Cap Smart patent cover?
The patent covers aspects of thermal insulation and smart monitoring, including a cap adaptable to different types of injection pens. VIVI Cap Smart launched earlier in 2026.